Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Receives Average Rating of “Hold” from Analysts

Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBHGet Free Report) have received an average recommendation of “Hold” from the twenty-one analysts that are presently covering the stock, Marketbeat Ratings reports. Two investment analysts have rated the stock with a sell rating, twelve have given a hold rating and seven have assigned a buy rating to the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $125.05.

Several research firms have recently weighed in on ZBH. Citigroup decreased their price target on shares of Zimmer Biomet from $134.00 to $120.00 and set a “neutral” rating on the stock in a research note on Wednesday, July 10th. UBS Group decreased their target price on shares of Zimmer Biomet from $112.00 to $107.00 and set a “sell” rating on the stock in a research note on Thursday, August 8th. Needham & Company LLC restated a “hold” rating on shares of Zimmer Biomet in a research report on Tuesday, September 17th. Oppenheimer cut their price target on Zimmer Biomet from $155.00 to $145.00 and set an “outperform” rating for the company in a report on Thursday, August 8th. Finally, JPMorgan Chase & Co. dropped their target price on Zimmer Biomet from $125.00 to $120.00 and set a “neutral” rating for the company in a report on Monday, September 16th.

View Our Latest Report on ZBH

Institutional Trading of Zimmer Biomet

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Park Avenue Securities LLC raised its holdings in shares of Zimmer Biomet by 158.6% in the 3rd quarter. Park Avenue Securities LLC now owns 5,249 shares of the medical equipment provider’s stock valued at $567,000 after buying an additional 3,219 shares during the period. SG Americas Securities LLC lifted its position in shares of Zimmer Biomet by 110.3% during the third quarter. SG Americas Securities LLC now owns 184,196 shares of the medical equipment provider’s stock worth $19,884,000 after purchasing an additional 96,593 shares in the last quarter. Czech National Bank boosted its stake in shares of Zimmer Biomet by 5.8% in the third quarter. Czech National Bank now owns 41,486 shares of the medical equipment provider’s stock valued at $4,478,000 after purchasing an additional 2,282 shares during the period. Massmutual Trust Co. FSB ADV grew its holdings in shares of Zimmer Biomet by 18.2% in the third quarter. Massmutual Trust Co. FSB ADV now owns 19,079 shares of the medical equipment provider’s stock valued at $2,060,000 after purchasing an additional 2,940 shares in the last quarter. Finally, M&R Capital Management Inc. increased its stake in Zimmer Biomet by 14.1% during the 3rd quarter. M&R Capital Management Inc. now owns 852 shares of the medical equipment provider’s stock worth $92,000 after buying an additional 105 shares during the period. Hedge funds and other institutional investors own 88.89% of the company’s stock.

Zimmer Biomet Trading Down 1.4 %

ZBH stock opened at $104.19 on Friday. The business’s 50-day moving average is $109.33 and its 200 day moving average is $114.30. Zimmer Biomet has a 12-month low of $102.00 and a 12-month high of $133.90. The stock has a market cap of $21.22 billion, a price-to-earnings ratio of 22.55, a PEG ratio of 1.94 and a beta of 1.02. The company has a current ratio of 1.29, a quick ratio of 0.63 and a debt-to-equity ratio of 0.31.

Zimmer Biomet (NYSE:ZBHGet Free Report) last issued its quarterly earnings results on Wednesday, August 7th. The medical equipment provider reported $2.01 EPS for the quarter, topping the consensus estimate of $1.99 by $0.02. The firm had revenue of $1.94 billion during the quarter, compared to analysts’ expectations of $1.94 billion. Zimmer Biomet had a return on equity of 12.86% and a net margin of 13.25%. The firm’s revenue for the quarter was up 3.9% on a year-over-year basis. During the same period in the previous year, the business earned $1.82 earnings per share. On average, sell-side analysts anticipate that Zimmer Biomet will post 8 EPS for the current fiscal year.

Zimmer Biomet Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, October 31st. Investors of record on Monday, September 30th will be given a dividend of $0.24 per share. The ex-dividend date of this dividend is Monday, September 30th. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.92%. Zimmer Biomet’s payout ratio is currently 20.78%.

About Zimmer Biomet

(Get Free Report

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.

Featured Articles

Analyst Recommendations for Zimmer Biomet (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.